INNOSTAR
68871071.210.58% ( +0.41 )
INNOSTAR (688710)
Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. It offers screening, nonclinical assessment s...
- Open
- 72.80
- High
- 75.46
- Low
- 70.82
- Prev. Close
- 70.80
- Volume
- 24.09K
- Turnover
- 175.42M
- Avg Price
- 72.81
- Bid/Ask Ratio
- --
- Amplitude
- 6.55%
- 52wk High
- 91.19
- Volume Ratio
- 0.39
- Turnover Ratio
- 2.66%
News
- PUBT · 20 hours ago
CEC Capital advises Zhongkexinyang on 100-million-yuan private financing round
- Unusual Whales · Jul 28 at 10:42 AM
Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle
- London Stock Exchange · Jul 28 at 05:06 AM
REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-Rez
- Unusual Whales · Jul 27 at 06:03 AM
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
- 同壁财经 · May 26 at 04:29 AM
INNOSTAR (688710): Won the procurement project of Tongji University, with a bid amount of 1.82 million yuan
- Wallstreetcn · Mar 19 at 01:30 AM
The A-share innovative drug concept fluctuated and declined, with SDKX falling over 10%. INNOSTAR, HITECK, Aidea Pharma, Chemexpress, and Beilu Pharma had significant declines
